Jakob Kræmmer Haar Rendsvig

Jakob Kræmmer Haar Rendsvig

Auto-generated profile, based on publicly available information

Jakob Kræmmer Haar Rendsvig

Bactolife A/S, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Protein Science
Verified
Journal Article
Open access
EREverardo Rodríguez
Everardo Rodríguez
RNRune Thorbjørn Nordvang
Rune Thorbjørn Nordvang
MPMarcus Petersson
Marcus Petersson
JRJakob Kræmmer Haar Rendsvig
Jakob Kræmmer Haar Rendsvig
EAEmma Wenzel Arendrup
Emma Wenzel Arendrup
STSandra Wingaard Thrane
Sandra Wingaard Thrane
Single‐domain antibodies (sdAbs), such as VHHs, are increasingly being developed for gastrointestinal (GI) applications against pathogens to strengthen gut health. However, what constitutes a suitable developability profile for applying these proteins in a gastrointestinal setting remains poorly explored. Here, we describe an in vitro methodology for the identification of sdAb derivatives, more specifically divalent VHH constructs, that display extraordinary developability properties for oral delivery and functionality in the GI environment. We showcase this by developing a heterodivalent VHH construct that cross‐inhibits the toxic activity of the glycosyltransferase domains (GTDs) from three different toxinotypes of cytotoxin B (TcdB) from lineages ofClostridium difficile. We show that the VHH construct possesses high stability and binding activity under gastric conditions, in the presence of bile salts, and at high temperatures. We suggest that the incorporation of early developability assessment could significantly aid in the efficient discovery of VHHs and related constructs fit for oral delivery and GI applications.

19 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMarcus Petersson
Marcus Petersson
FZFranz Zingl
Franz Zingl
EREverardo Rodríguez
Everardo Rodríguez
JRJakob K. H. Rendsvig
Jakob K. H. Rendsvig
HHHeidi Heinsøe
Heidi Heinsøe
STSandra Wingaard Thrane
Sandra Wingaard Thrane
The ongoing seventh cholera pandemic, which began in 1961, poses an escalating threat to public health. There is a need for new cholera control measures, particularly ones that can be produced at low cost, for the one billion people living in cholera-endemic regions. Orally delivered VHHs, functioning as target-binding proteins, have been proposed as a potential approach to control gastrointestinal pathogens. Here, we describe the development of an orally deliverable bivalent VHH construct that binds to the B-pentamer of cholera toxin, showing that it inhibits toxin activity in a murine challenge model. Infant mice given the bivalent VHH prior to V. cholerae infection exhibit a significant reduction in cholera toxin–associated intestinal fluid secretion and diarrhoea. In addition, the bivalent VHH reduces V. cholerae colonization levels in the small intestine by a factor of 10. This cholera toxin–binding protein holds promise for protecting against severe diarrhoea associated with cholera.